The intravenous injectible is used to raise blood pressure in adults with certain symptoms like sepsis, shock, and hypertension, but can also cause dangerous blood clots. The agency warns that use of this drug should be in conjunction with prophylactic treatments.
In a 321 patient clinical trial Giapreza raised blood pressure against placebo tests, and received a 'Priority Review' from the FDA, which expedites application actions to within 6 months. You can read the full press release here.
© New Kapitall Holdings LLC. All rights reserved. Kapitall Wire is a division of New Kapitall Holdings LLC. Kapitall Generation, LLC is a wholly owned subsidiary of New Kapitall Holdings LLC. Kapitall Wire, which is not a broker/dealer, offers free cutting edge content and commentary and is produced for informational purposes only and should not be construed as research. Kapitall Wire is a product offered by New Kapitall Holdings, however, KapGen compliance personnel will oversee all Kapitall Wire material prior to release.